The current version of the androgen receptor (AR) gene mutations database is described. We have added (if available) data on the androgen binding phenotype of the mutant AR, the clinical phenotype of the affected persons, the family history and whether the pathogenicity of a mutation has been proven. 
INTRODUCTION
Constitutional mutations in the androgen receptor gene (AR) impair androgen-dependent male sexual differentiation to various degrees (1) (2) (3) (4) (5) (6) (7) . Somatic mutations in the AR have been found in metastatic prostate cancer (8) . Severe constitutional androgen insensitivity (AI) yields an external female phenotype. Partial constitutional AI yields a range of external genital phenotypes that vary from near normal female to normal or near normal male, with or without gynecomastia and other relatively 'mild' signs of undervirilization. Some have suggested that clinical severity of AI be divided into three degrees: complete, partial (when there is appreciable external genital ambiguity) and mild (for the least severe forms). Others have graded severity into seven degrees (1). The current version of the AR database retains the complete/partial bifurcation of the original database (7), but provides additional information on the external genitalia and on sex-ofrearing (Table 1) . When external genital ambiguity is appreciable the sex-of-rearing implies that the external genitalia were predominately male or female. Because different clinical degrees of AI are sometimes seen within families or between those with the same mutation, the new version of the database has an entry for family history.
There are various ways to characterize the androgen binding activity of a mutant AR. In addition to B max and K d , the new version of the database provides for k, the off-rate of androgen from androgen-receptor (A-R) complexes, and for thermolability of A-R complex formation. Each of these values may be abnormal when the other three are normal.
Ultimately it is essential to prove that a given AR mutation is causally related to an AI or prostate cancer phenotype. Usually this is done by recreating the mutation in an AR cDNA and demonstrating an AR abnormality after transfection into AR-free host cells. Therefore, the new version of the database has an entry to show if pathogenicity has been proven.
This version of the database has several structural alterations to improve user friendliness. For instance, the mutations are listed in a simple 5′→3′ sequence regardless of their type and 1-3-base pair changes are indicated in codon context. The previous version first lumped particular types of mutations and then listed them sequentially. It also gave single base changes out of codon context, in order to visualize CpG sites directly. This version has a separate entry for CpG sites.
DATABASE INFORMATION
This version of the database contains 212 entries (Table 2) representing 239 patients with AI or prostate cancer bearing 155 different AR mutations (Fig. 1) . In the previous version the corresponding numbers are each ∼33% smaller.
There has been a disproportionate increase in exon 1 mutations reported. Expectedly, in view of the low degree of amino acid conservation in the N-terminal region of steroid receptors, most of the exon 1 mutations are premature stops with or without prior frame-shifts due to deletion or insertion. Remarkably, however, four of the 12 exon 1 mutations cause amino acid substitutions. It will be important to understand the mechanism(s) by which these four impair androgen sensitivity.
The distribution of mutations in the coding and intronic portions of the AR is shown in Figure 1 . Apart from the relative paucity of mutations in exon 1 and some gaps in exons 2-8, the outstanding feature of the distribution is the relative excess of mutations in or around exons 5 and 7. An analysis based on many fewer mutations had called attention to these regions previously (9) . Using the current version of the database we have analyzed 87 missense or stop mutations in the androgen binding domain of the AR to amplify the previous study and to extend it in two ways. As shown in Figure 2 , 'hot spot 1' contains 37% of the 87 mutations and these mutations affect 68% of the available codons ('mutation density') in that region. While 'hot spot 2' contains only 18% of the 87 mutations, a frequency not different from those in the three regions between or flanking the hot spots, it does have a mutation density (39%) that makes it stand out from the other three regions. Interestingly, 44% of the mutations in 'hot spot 2' occurred at CpG sites. The corresponding value for 'hot spot 1' is only 22%. Thus the region around exon 5 bears mutations much beyond its CpG-dependent susceptibility to mutagenesis.
DATABASE AVAILABILITY AND CITATION
The database is now available via anonymous ftp server at ftp://www.ebi.ac.uk/pub/databases/androgen. The database can also be obtained as a Macintosh Filemaker file from Bruce Gottlieb (MC33@musica.mcgill.ca). The database is updated every 3-4 months. Users are requested to cite the present article when they have used the database for their publications. Research Council, Canada, the Fonds de la Recherche en Santé, Québec and the Fonds pour la Formation de Chercheurs et l'Aide à la Recherche, Quebec for supporting our own work on AR mutations.
